<!DOCTYPE html>

<!-- paulirish.com/2008/conditional-stylesheets-vs-css-hacks-answer-neither/ -->
<!--[if lt IE 7]> <html class="no-js lt-ie9 lt-ie8 lt-ie7" lang="en"> <![endif]-->
<!--[if IE 7]>    <html class="no-js lt-ie9 lt-ie8" lang="en"> <![endif]-->
<!--[if IE 8]>    <html class="no-js lt-ie9" lang="en"> <![endif]-->
<!--[if gt IE 8]><!--> <html class="no-js" lang="en"> <!--<![endif]-->
<head>
	<meta charset="utf-8" />

	<!-- Set the viewport width to device width for mobile -->
	<meta name="viewport" content="width=device-width" />

	<title>PracticeUpdate : News Item</title>

	<!-- Included CSS Files -->
<!-- FontDeck
<link rel="stylesheet" href="http://f.fontdeck.com/s/css/l4MsFun30OJhB9DTDGcb8JQSAOQ/practicenetwork-foundation/22889.css" type="text/css" />
-->

	<link rel="stylesheet" href="assets/css/app.css">
	<link rel="stylesheet" href="assets/css/font-awesome.css">
	<link rel="stylesheet" href="assets/css/fc-webicons.css">
	<link rel="stylesheet" href="assets/css/foundation-icons-general.css">

	<script src="assets/js/foundation/modernizr.foundation.js"></script>

	<!-- sharethis code -->
<script type="text/javascript">var switchTo5x=true;</script>
<script type="text/javascript" src="http://w.sharethis.com/button/buttons.js"></script>
<script type="text/javascript">stLight.options({publisher: "f3b4e78b-9a7f-4bd8-900f-c0b05425275f", doNotHash: true, doNotCopy: true, hashAddressBar: false});</script>

<!-- End sharethis -->

<!-- VideoJS -->
  <!-- Chang URLs to wherever Video.js files will be hosted -->
  <link href="assets/css/video-js.css" rel="stylesheet" type="text/css">
  <!-- video.js must be in the <head> for older IEs to work. -->
  <script src="assets/js/video.min.js"></script>
<!-- END VideoJS -->

	<!-- IE Fix for HTML5 Tags -->
    <!--[if lt IE 9]>
        <script src="http://html5shiv.googlecode.com/svn/trunk/html5.js"></script>
    <![endif]-->

    <!-- redline.cc test -->
<!-- <script id="redline_js" type="text/javascript">var redline = {}; redline.project_id = 126632090;var b,d;b=document.createElement("script");b.type="text/javascript";b.async=!0;b.src=("https:"===document.location.protocol?"https://data":"http://www")+'.redline.cc/assets/button.js';d=document.getElementsByTagName("script")[0];d.parentNode.insertBefore(b,d);</script> -->
    <!-- end redline script -->

</head>
	<body id="page" class="update off-canvas slide-nav news-item logged-out">
  <div class="widget ad">
    <div id="leaderboard" class="Breast ad-container">
      <div class="ad-title"><span class="ad-title-text">advertisement</span></div><!--/.ad-title-->
      <div id="leaderboardcontent" class="ad-content">
			</div><!--.ad-content-->
		</div><!--/#leaderboard.ad-container-->
  </div><!--/.widget.ad-->
	<div class="page-header">
	</div><!--/.page-header-->
	<div class="page-content">
	<section role="main">

<div class="single-item-container">
	<article class="type-blog single-item">
	<div class="item-header-container">
		<header class="item-header">
			<div class="flag-container"><span class="flag featured"><i class="icon-bolt"></i> featured</span></div>
			<div class="meta pub-meta">
				<span class="item-type">News</span>
				<span class="item-pub-date"><time datetime="12-12-05">December 05, 2012</span>
			</div>
			<hgroup class="item-title-container">
				<h1 class="item-title">Second-Line FOLFIRI/Aflibercept Ups Survival in Metastatic Colorectal Cancer</h1>
				<p class="item-citation">{{source.citation}}</p>
			</hgroup>

		<div class="action-bar" style="padding-bottom:17px;">
			<div class="socialshare-actions">
					<span class='ss_facebook has-tip tip-top' title="share on facebook"><i class="icon-facebook-sign"></i></span>
					<span class='ss_twitter has-tip tip-top' title="share on facebook"><i class="icon-twitter-sign"></i></span>
					<span class='ss_googleplus has-tip tip-top' title="share on facebook"><i class="icon-google-plus-sign"></i></span>
					<span class='ss_linkedin has-tip tip-top' title="share on facebook"><i class="icon-linkedin-sign"></i></span>
					<span class='ss_email has-tip tip-top' title="send this via email"><i class="icon-envelope-alt"></i></span>
					<span class='ss_print has-tip tip-top' title="print this page"><i class="icon-print"></i></span>
			</div><!--/.ssocialshare-actions-->
		</div><!--/.action-bar-->


				<!-- <p class="source"> --><!-- {{source}} --><!-- J Clin Oncol. 2012 Aug 27;[Epub Ahead of Print], HSL Jim, KM Phillips, S Chait</p>--><!--/.source-->
				<!-- <h2 class="item-subtitle">Article Subtitle - Optional</h2> -->
			<!-- <div class="item-description">
				<p>In this commentary, Dr. Scher discusses his research on a novel androgen receptor signaling inhibitor, MDV3100, which was shown to improve survival in a post-chemotherapy population of men with progressive castration-resistant prostate cancer (CRPC).</p>
			</div> --><!--/.description-->
				<!-- <div class="meta taxonomy-meta">
				<p>Find more items about these topics:</p>
				<ul class="tag-list">
					<li>
						<i class="icon-tags"></i><a class="label label-tag" href="#">Prostate</a>
					</li> -->
				<!-- </ul> --><!--/.tag-list-->
			<!-- </div> --><!--/.taxonomy-meta-->
		</header>
	</div><!--/.item-header-container-->
	<div class="item-content-container">
		<div class="item-content">
			<div class="item-content-section">
				<section class="story">
				<div class="story-image-group">
						<figure>
							<img src="/content/img/feed/2400A6A7_us.jpg" />
							<figcaption>Name of Dude</figcaption>
						</figure>
						<figure>
							<img src="/content/img/feed/2400A6A7_us.jpg" />
							<figcaption>Name of Dude</figcaption>
						</figure>
					</div>
							<p>
								Metastatic colorectal cancer is generally treated initially with a regimen of fluorouracil and leucovorin plus either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI). Patients cross over to the alternate regimen for second-line therapy. The antiangiogenic agent bevacizumab has been shown to increase survival in patients with metastatic colorectal cancer in the first-line setting when added to FOLFIRI and in the second-line setting when added to FOLFOX, but no biologic agent has been shown to improve survival in the second-line setting when added to FOLFIRI.</p><p>Aflibercept is a recombinant fusion protein that targets three factors that contribute to tumor angiogenesis: vascular endothelial growth factor A (VEGFA), VEGFB, and placental growth factor (PlGF). In a multinational phase III study sponsored by Sanofi, Van Cutsem et al added aflibercept to FOLFIRI as second-line therapy for metastatic colorectal cancer previously treated with oxaliplatin. Prior bevacizumab was allowed, but not prior irinotecan.</p><p>Between 2007 and 2010, a total of 1226 patients were randomized to receive aflibercept 4 mg/kg (n = 612) or placebo (n = 614) on day 1 every 2 weeks, followed by the FOLFIRI regimen (irinotecan 180 mg/m2, leucovorin 400 mg/m2, and fluorouracil 400 mg/m2 bolus and then 2400 mg/m2 by continuous infusion). Crossover to aflibercept after progression on placebo was not permitted.</p><p>At the February 2011 cutoff date for analysis of overall survival (OS), the primary endpoint, median follow-up was 22.28 months. The patients receiving aflibercept/FOLFIRI had a median survival of 13.50 months compared with 12.06 months for the placebo/FOLFIRI control patients (hazard ratio [HR], 0.817; P = .0032). At 2 years, survival rates were 28.0% and 18.7%, respectively. The treatment effect favoring aflibercept held in analyses of prespecified subgroups based on prior bevacizumab use and various patient characteristics at baseline.</p><p>Progression-free survival (PFS) increased from 4.7 months for controls to 6.9 months with use of aflibercept (HR, 0.758; P &lt; .0001). Subgroup analyses showed a consistent trend in PFS in favor of aflibercept. The response rate in patients with measurable disease was significantly higher with aflibercept vs placebo (19.8% vs 11.1%; P &lt; .001).</p><p>Grade 3 and 4 adverse events were more common with aflibercept than placebo (83.5% vs 62.5%, respectively). Toxicities related to anti-VEGF treatment were consistent with those reported in previous studies. Interestingly, some common adverse events related to treatment with FOLFIRI were more frequent in the aflibercept arm. These included grade 3 and 4 diarrhea, asthenia, stomatitis, infections, and palmar&#8211;plantar erythrodysesthesia, as well as grade 3 and 4 neutropenia, thrombocytopenia, and neutropenic complications.</p><p>The addition of aflibercept to FOLFIRI led to a relative reduction in the risk of death of 18.3%, compared with placebo/FOLFIRI. The early and continued divergence of the survival curves further supports the clinical value of the aflibercept results. Survival rates for aflibercept vs placebo were 38.5% vs 30.9% at 18 months, 28.0% vs 18.7% at 24 months, and 22.3% vs 12.0% at 30 months.</p><p>The authors concluded that aflibercept plus FOLFIRI may be a new therapeutic option for the treatment of metastatic colorectal cancer patients whose disease has progressed while on or after completion of an oxaliplatin-based regimen.</p>
				</section><!-- /.story-->
			</div><!-- ./item-content-section -->
			<div class="item-content-section">
				<section class="video">
<div class="flex-video">
  <!-- <iframe width="420" height="315" src="http://www.youtube.com/embed/9otNWTHOJi8" frameborder="0" allowfullscreen></iframe> -->
  <iframe width="560" height="315" src="http://www.youtube.com/embed/b6Tmu7LLKEs" frameborder="0" allowfullscreen></iframe>
</div>
</section><!--/.video-->
</div><!--/.item-content-section-->
				<hr />
		</div><!--/.item-content-->
	</div><!--/.item-content-container-->
<footer class="copyright item-footer">
<img class="logo" src="content/img/feed/imng_logo.gif" alt="IMNG Medical Media"/>
<p>Copyright &copy; 2012 International Medical News Group</p>
</footer>
</div><!--/.item-container-->
				<div id="aux" class="recommended">
				<div id="cta-moa" class="cta">
          <div class="cta-title"><span class="cta-title-text"><a data-reveal-id="modal-video-ad">Learn about the MOA of a Kinase Inhibitor for Thyroid Cancer Treatment</a></span></div><!--/.cta-title-->
        	<div class="cta-img-container">
        		<a class="th" data-reveal-id="modal-video-ad" style="display:block;"><img src="/content/img/cta/cta-image-moa.jpg" alt="Click to Play Video"></a>
        	</div><!--/.cta-img-container-->
				</div><!--/#cta-moa.cta-->
				<div class="recent">
				</div><!--/.recent-->
				<div class="ad">
					<img src="http://placehold.it/300x250" align="ad" title="ad" />
				</div>
				</div><!--/.recommended-->

	</section><!--/[role="main"]-->
	<section id="sidebar" role="complementary">
		<div class="dashboard">
			<div class="panel cta register">
				<p><!-- Meet Our Experts --> Become a member to customize this page.<p>
				<a class="button" href="#action-register">Register for free</a>
			</div><!--/.panel.cta.register-->
			<div class="component user-console">
			</div><!--/.component.user-console-->

			<div class="component user-topic">
			</div><!--/.component.user-topic-->
			<div class="component topic-spotlight">
			</div><!--/.component.topic-spotlight-->
			<div class="panel">
				<img src="http://placehold.it/200x200" /><p><!-- Meet Our Experts --> Meet our Advisory and Editorial Boards comprised of physician editors and world-renowned experts.<p>
			</div>
		</div><!--/.sidebar-->
	</section><!--/.[role="complimentary"]-->
</div><!--/.page-content-->
	<div class="page-footer-container">
  	<footer class="page-footer">
  	</footer><!-- /.page-footer -->
	</div><!-- /.page-footer-container -->
	<!-- Included JS Files (Uncompressed) -->
  <script src="assets/js/foundation/jquery.js"></script>

	<script src="assets/js/foundation/jquery.foundation.accordion.js"></script>
	<script src="assets/js/foundation/jquery.foundation.alerts.js"></script>
	<script src="assets/js/foundation/jquery.foundation.buttons.js"></script>
	<script src="assets/js/foundation/jquery.foundation.forms.js"></script>
	<script src="assets/js/foundation/jquery.foundation.mediaQueryToggle.js"></script>
	<script src="assets/js/foundation/jquery.foundation.navigation.js"></script>
	<script src="assets/js/foundation/jquery.foundation.orbit.js"></script>
	<script src="assets/js/foundation/jquery.foundation.reveal.js"></script>
	<script src="assets/js/foundation/jquery.foundation.tabs.js"></script>
	<script src="assets/js/foundation/jquery.foundation.tooltips.js"></script>
	<script src="assets/js/foundation/jquery.placeholder.js"></script>


	<script src="assets/js/foundation/app.js"></script>
	<script src="assets/js/foundation/jquery.offcanvas.js"></script>


	<script src="assets/js/mustache.js"></script>

	<!-- Placeholder - for replacing placeholder images -->
	<script src="assets/js/holder.js"></script>

	<!-- Page Modal -->
	<div id="modal-video-ad" class="reveal-modal">
<div class="modal-header">
<h3>
    Learn about the MOA of a Kinase Inhibitor for Thyroid Cancer Treatment
</h3>
<!-- <p class="cme-description">An interactive CME activity provided by the Johns Hopkins University School of Medicine</p> -->
  </div><!--/.modal-header-->
  <div class="modal-body">
<div class="flex-video vimeo">
		<iframe src="http://player.vimeo.com/video/62871530" width="500" height="281" frameborder="0" webkitAllowFullScreen mozallowfullscreen allowFullScreen></iframe>
</div>
  </div><!--/.modal-body-->
  <div class="modal-footer">
    <p><a href="http://www1.astrazeneca-us.com/pi/" target="_blank" rel="external">See accompanying full Prescribing Information for CAPRELSA, including Boxed WARNING and Medication Guide.</a></p>
  </div><!--/.modal-footer-->
<a class="close-reveal-modal">Ã—</a>
	</div><!-- /.modal-video-ad-->

</body>
</html>